TriangleDISEASE & TREATMENT SETTING
Lung Carcinoma
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Lung Carcinoma
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Added because the terminology and the registry both attest it: an NCIt neoplasm concept named by 39 acquired study condition(s). It is absent from the NCI treatment-topic directory, which is not an exhaustive cancer inventory.
- source wording
- Source null
2 more-specific settings
Study evidence for this setting
Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Bupropion in Helping Adults Stop Smoking
Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Acceptability of Less Harmful Alternatives to Cigarettes
Validation of a Screening Tool in Geriatric Oncology
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
Indication-specific source history
2020-05-08 · Retevmo (selpercatinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-dd76ce3b980a0820
- event date
- 2020-05-08
- event kind
- accelerated-approval
- drug or regimen
- Retevmo (selpercatinib)
- source indication text
- Adult patients with metastatic RET fusion-positive Non-Small Cell Lung Cancer (NSCLC)
- match phrase
- lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-e3591ea14459aba9db9d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-06-15 · Zepzelca (lurbinectedin) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-9298d5fd19225e5c
- event date
- 2020-06-15
- event kind
- accelerated-approval
- drug or regimen
- Zepzelca (lurbinectedin)
- source indication text
- Treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-0ad64c5b6a6d3d39fe10
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2020-09-04 · Gavreto (pralsetinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-09ce96ddfc864901
- event date
- 2020-09-04
- event kind
- accelerated-approval
- drug or regimen
- Gavreto (pralsetinib)
- source indication text
- Treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test
- match phrase
- lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f1bd2f76ea52efe6c081
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-02-03 · Tepmetko (tepotinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-c38fb46e1d42f141
- event date
- 2021-02-03
- event kind
- accelerated-approval
- drug or regimen
- Tepmetko (tepotinib)
- source indication text
- Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
- match phrase
- lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-c23b04eb67672e5e0497
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-05-21 · Rybrevant (amivantamab-vmjw) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-2db75e2eb17cb505
- event date
- 2021-05-21
- event kind
- accelerated-approval
- drug or regimen
- Rybrevant (amivantamab-vmjw)
- source indication text
- Treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum based chemotherapy
- match phrase
- lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-37d888930f4674daf5ef
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-05-28 · Lumakras (sotorasib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-9ed32ca2bb5fe831
- event date
- 2021-05-28
- event kind
- accelerated-approval
- drug or regimen
- Lumakras (sotorasib)
- source indication text
- Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-1560c86153e4a495fb2c
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2021-09-15 · Exkivity (mobocertinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-bf7a5aebbe84a1c9
- event date
- 2021-09-15
- event kind
- accelerated-approval
- drug or regimen
- Exkivity (mobocertinib)
- source indication text
- Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
- match phrase
- lung cancer
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-21fd32ccc7ace4c77d83
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2022-09-21 · Retevmo (selpercatinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-df35cefb104e0515
- event date
- 2022-09-21
- event kind
- traditional-approval
- drug or regimen
- Retevmo (selpercatinib)
- source indication text
- Adult patients with metastatic RET fusion-positive Non-Small Cell Lung Cancer (NSCLC)
- match phrase
- lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-e3591ea14459aba9db9d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2022-12-12 · Krazati (adagrasib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-3d8647b6e644dd83
- event date
- 2022-12-12
- event kind
- accelerated-approval
- drug or regimen
- Krazati (adagrasib)
- source indication text
- Adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-07225e854ead88e41b45
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2023-08-09 · Gavreto (pralsetinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-c909ea00792cf068
- event date
- 2023-08-09
- event kind
- traditional-approval
- drug or regimen
- Gavreto (pralsetinib)
- source indication text
- Treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test
- match phrase
- lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-f1bd2f76ea52efe6c081
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-02-15 · Tepmetko (tepotinib) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-9385f3cdc63d9f85
- event date
- 2024-02-15
- event kind
- traditional-approval
- drug or regimen
- Tepmetko (tepotinib)
- source indication text
- Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
- match phrase
- lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-c23b04eb67672e5e0497
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-03-01 · Rybrevant (amivantamab-vmjw) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-355364b2b8809d0b
- event date
- 2024-03-01
- event kind
- traditional-approval
- drug or regimen
- Rybrevant (amivantamab-vmjw)
- source indication text
- Treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA approved test, whose disease has progressed on or after platinum based chemotherapy
- match phrase
- lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-37d888930f4674daf5ef
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-05-16 · Imdelltra (tarlatamab-dlle) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-b2a35965afd02ba8
- event date
- 2024-05-16
- event kind
- accelerated-approval
- drug or regimen
- Imdelltra (tarlatamab-dlle)
- source indication text
- Adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
- match phrase
- lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-2ddd2b249830a3d5e47e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-07-15 · Exkivity (mobocertinib) · withdrawal
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-c6244566cc233929
- event date
- 2024-07-15
- event kind
- withdrawal
- drug or regimen
- Exkivity (mobocertinib)
- source indication text
- Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy
- match phrase
- lung cancer
- match status
- candidate
- status category
- withdrawn
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-21fd32ccc7ace4c77d83
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2024-12-04 · Bizengri (zenocutuzumab-zbco) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-82c4064f349aeb36
- event date
- 2024-12-04
- event kind
- accelerated-approval
- drug or regimen
- Bizengri (zenocutuzumab-zbco)
- source indication text
- Treatment of adults with advanced unresectable or metastatic nonsmall cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-72f1a2513efccd59cb74
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-05-14 · Emrelis (telisotuzumab vedotin-tllv) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-bc852a4da8a2bac4
- event date
- 2025-05-14
- event kind
- accelerated-approval
- drug or regimen
- Emrelis (telisotuzumab vedotin-tllv)
- source indication text
- Treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test, who have received a prior systemic therapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-1bdc47f45493f905a5e7
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-05-14 · telisotuzumab vedotin-tllv · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-38cedb0416e82930
- event date
- 2025-05-14
- event kind
- approval-notification
- drug or regimen
- telisotuzumab vedotin-tllv
- source indication text
- FDA approved telisotuzumab vedotin-tllv, a c-Met-directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein overexpression [≥50% of tumor cells with strong staining], as determined by an FDA-approved test, who have received a prior systemic therapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-2f7de233a4d4da06
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-06-11 · taletrectinib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-1cb6dedb9747d8bb
- event date
- 2025-06-11
- event kind
- approval-notification
- drug or regimen
- taletrectinib
- source indication text
- FDA approved taletrectinib, a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer .
- match phrase
- lung cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-0f7fd15d941ce1a4
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-06-23 · Datroway (datopotamab deruxtecan-dlnk) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-db0545bbaf1a88f9
- event date
- 2025-06-23
- event kind
- accelerated-approval
- drug or regimen
- Datroway (datopotamab deruxtecan-dlnk)
- source indication text
- Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-b29e6e916d89560e828a
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-06-23 · datopotamab deruxtecan-dlnk · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-14574e0567a1c83b
- event date
- 2025-06-23
- event kind
- approval-notification
- drug or regimen
- datopotamab deruxtecan-dlnk
- source indication text
- FDA approved datopotamab deruxtecan-dlnk for adults with locally advanced or metastatic epidermal growth factor receptor -mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-29743855ffd67cd9
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-07-02 · Zegfrovy (sunvozertinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-1b628574904396b6
- event date
- 2025-07-02
- event kind
- accelerated-approval
- drug or regimen
- Zegfrovy (sunvozertinib)
- source indication text
- Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-079ab36594871b1f41b2
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-07-02 · sunvozertinib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-f7921acfacebfe74
- event date
- 2025-07-02
- event kind
- approval-notification
- drug or regimen
- sunvozertinib
- source indication text
- FDA approved sunvozertinib for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-29a56844a8ee9ae3
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-08-08 · Hernexeos (zongertinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-1270b9a947c2ad5f
- event date
- 2025-08-08
- event kind
- accelerated-approval
- drug or regimen
- Hernexeos (zongertinib)
- source indication text
- Treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA approved test, and who have received prior systemic therapy
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-54553a738243b9da33e1
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-08-08 · zongertinib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-cafba315242daf03
- event date
- 2025-08-08
- event kind
- approval-notification
- drug or regimen
- zongertinib
- source indication text
- FDA approved zongertinib, a kinase inhibitor, for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-7d091a8440ce03e5
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-10-02 · lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-aad957c7d413616a
- event date
- 2025-10-02
- event kind
- approval-notification
- drug or regimen
- lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs
- source indication text
- FDA approved lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide.
- match phrase
- lung cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-2552276b0d3a31f8
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-11-19 · Hyrnuo (sevabertinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-2bbdc85ad026f270
- event date
- 2025-11-19
- event kind
- accelerated-approval
- drug or regimen
- Hyrnuo (sevabertinib)
- source indication text
- Treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-daaf01f51985f0cf8178
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-11-19 · Imdelltra (tarlatamab-dlle) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-34bbe73207e89dbb
- event date
- 2025-11-19
- event kind
- traditional-approval
- drug or regimen
- Imdelltra (tarlatamab-dlle)
- source indication text
- Adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy
- match phrase
- lung cancer
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-2ddd2b249830a3d5e47e
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-11-19 · sevabertinib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-bb73eb55a548e6da
- event date
- 2025-11-19
- event kind
- approval-notification
- drug or regimen
- sevabertinib
- source indication text
- FDA approved sevabertinib, a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.
- match phrase
- lung cancer
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-26f47f4afac6d968
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-11-19 · tarlatamab-dlle · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-bf7e6d14689c01f9
- event date
- 2025-11-19
- event kind
- approval-notification
- drug or regimen
- tarlatamab-dlle
- source indication text
- FDA approved tarlatamab-dlle for adults with extensive stage small cell lung cancer with disease progression on or after platinum-based chemotherapy. Tarlatamab-dlle received accelerated approval for this indication in 2024.
- match phrase
- lung cancer
- match status
- candidate
- status category
- traditional
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-a0a0b26c2d3a3702
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-02-26 · Hernexeos (zongertinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-e6c39cb199f7bd4f
- event date
- 2026-02-26
- event kind
- accelerated-approval
- drug or regimen
- Hernexeos (zongertinib)
- source indication text
- Treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations, as detected by an FDA-authorized test
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-acf999b5dcbb789c416e
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-02-26 · zongertinib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-c9e3c49c95b26232
- event date
- 2026-02-26
- event kind
- approval-notification
- drug or regimen
- zongertinib
- source indication text
- FDA approved zongertinib, a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.
- match phrase
- lung cancer
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-3a7f03155778019c
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-07-22 · zidesamtinib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-2ae43f5d8ca8e345
- event date
- 2026-07-22
- event kind
- approval-notification
- drug or regimen
- zidesamtinib
- source indication text
- FDA approved zidesamtinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received at least one prior ROS1 tyrosine kinase inhibitor .
- match phrase
- lung cancer
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-e0f74c6ff06b5fd4
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-09-09 · Hyrnuo (sevabertinib) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- fda-1008e60858d8505e
- event date
- 2026-09-09
- event kind
- accelerated-approval
- drug or regimen
- Hyrnuo (sevabertinib)
- source indication text
- Treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test
- match phrase
- lung cancer
- match status
- candidate
- status category
- ongoing
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-1fbc5cf6f5df6b5af351
- source url
- https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-09-09 · sevabertinib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- event id
- notice-e7c4c6dfc1bcdd71
- event date
- 2026-09-09
- event kind
- approval-notification
- drug or regimen
- sevabertinib
- source indication text
- FDA approved sevabertinib, a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.
- match phrase
- lung cancer
- match status
- candidate
- status category
- accelerated
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-31fccf3ff6d99d7d
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-lung-carcinoma
- binding id
- ncit-C4878
- source collection
- ncit-concept
- source key
- C4878
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice